ERNA
Eterna Therapeutics Inc
NASDAQ: ERNA · HEALTHCARE · BIOTECHNOLOGY
$0.15
-21.24% today
Updated 2026-04-30
Market cap
$5.59M
P/E ratio
—
P/S ratio
1,275.37x
EPS (TTM)
$-2.24
Dividend yield
—
52W range
$0 – $4
Volume
1.1M
WallStSmart proprietary scores
19
out of 100
Grade: F
Strong Sell
Investment rating
3.7
Growth
D5.0
Quality
C+3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
-67.2
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$3.00
+1932.52%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
X-Ray snapshot
Strengths
+ Debt/equity 0.15x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -67.20 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-1.16M
- Revenue declining -94.10% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $68000.00 | $582000.00 | $0.00 | $1000.00 |
| Net income | $-24.58M | $-21.67M | $-44.54M | $-14.10M | $-1.50M |
| EPS | — | — | — | — | $-2.24 |
| Free cash flow | $-21.27M | $-20.43M | $-16.20M | $-7.05M | $-1.16M |
| Profit margin | — | -31,864.71% | -7,652.75% | — | — |
Peer comparison
Smart narrative
Eterna Therapeutics Inc trades at $0.15. Our Smart Value Score of 19/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -67.20, it sits in the distress. TTM revenue stands at $1000.00.
Frequently asked questions
What is Eterna Therapeutics Inc's stock price?
Eterna Therapeutics Inc (ERNA) trades at $0.15.
Is Eterna Therapeutics Inc overvalued?
Smart Value Score 19/100 (Grade F, Strong Sell).
What is the price target of Eterna Therapeutics Inc (ERNA)?
The analyst target price is $3.00, representing +1932.5% upside from the current price of $0.15.
What is Eterna Therapeutics Inc's revenue?
TTM revenue is $1000.00.
Piotroski F-Score?
1/9 — weak financial health.
Altman Z-Score?
-67.20 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1,275.37x
ROE-687.00%
Beta6.85
50D MA$0.26
200D MA$1.10
Shares out0.03B
Float0.02B
Short ratio—
Avg volume1.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—